InhaleRx Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRX.AX research report →
Price Chart
About the company
Established in 2016 and headquartered in Sydney, Australia, InhaleRx Limited is an Australian company primarily engaged in advancing and bringing to market medical drug delivery systems. The firm also dedicates efforts to developing specialized inhaled drug formulations. A notable product within its portfolio is the Medihale inhaler, a distinctive sealed-pod device engineered for compatibility with its inhaled medications.
- CEO
- Darryl Davies
- IPO
- 2017
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on IRX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.90M
- P/E
- -4.67
- PEG
- 0.09
- P/S
- 20.58
- P/B
- -93.42
- EV/EBITDA
- -6.01
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -396.04%
- Net Margin
- -380.81%
- ROE
- -424.30%
- ROIC
- 3073.55%
Latest fiscal year · YoY change
- Revenue
- $335.10K-72.2%
- Gross Profit
- $335.10K-72.2%
- Op Income
- $-1,327,132
- Net Income
- $-1,276,087+11.6%
- EPS
- $-0.01+21.1%
- OCF Growth
- +81.2%
- FCF Growth
- +81.2%
- 52W High
- $0.05
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- -0.29
- RSI (14)
- 46
- Avg Volume
- 205.01K
No earnings-call transcripts are available for IRX.AX yet.
- Free Float
- 67.2%
- Shares Outstanding
- 246.26M
- Float Shares
- 165.47M
Our IRX.AX coverage
Recent articles, reports, and earnings notes.
No research on IRX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRX.AX report →